Abstract
The development of bisphosphonates and anti-RANK/RANKL agents was associated with a better understanding of physiological and pathological processes of bone remodeling. New agents are now developed in this context targeting factors associated with osteoclastogenesis (TGFβ, PTHrP), with signaling pathways activated during bone remodeling (Src, Cathepsin K) or with tumor cells homing into bone (chemokines). This review aims to present the underlying rationale for these developments as well as the clinical results. The emergence of new bone targeting therapies is discussed.
Keywords:
bone targeted therapies.
MeSH terms
-
Aniline Compounds / therapeutic use
-
Benzodioxoles / therapeutic use
-
Bone Density Conservation Agents / therapeutic use*
-
Bone Resorption / drug therapy*
-
Bone Resorption / etiology
-
Cathepsin K / antagonists & inhibitors
-
Dasatinib
-
Diphosphonates / therapeutic use*
-
Humans
-
Molecular Targeted Therapy / methods*
-
Nitriles / therapeutic use
-
Parathyroid Hormone-Related Protein / antagonists & inhibitors
-
Pyrimidines / therapeutic use
-
Quinazolines / therapeutic use
-
Quinolines / therapeutic use
-
RANK Ligand / antagonists & inhibitors
-
Receptors, Chemokine / antagonists & inhibitors
-
Thiazoles / therapeutic use
-
Transforming Growth Factor beta1 / antagonists & inhibitors
-
src-Family Kinases / antagonists & inhibitors*
-
src-Family Kinases / metabolism
Substances
-
Aniline Compounds
-
Benzodioxoles
-
Bone Density Conservation Agents
-
Diphosphonates
-
Nitriles
-
Parathyroid Hormone-Related Protein
-
Pyrimidines
-
Quinazolines
-
Quinolines
-
RANK Ligand
-
Receptors, Chemokine
-
Thiazoles
-
Transforming Growth Factor beta1
-
bosutinib
-
saracatinib
-
src-Family Kinases
-
Cathepsin K
-
Dasatinib